Larimar Therapeutics, Inc. (NASDAQ:LRMR – Get Free Report)’s share price crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $2.93 and traded as high as $3.08. Larimar Therapeutics shares last traded at $3.02, with a volume of 2,531,459 shares.
Larimar Therapeutics News Summary
These are some of the LRMR news items that stood out recently:
- Positive Sentiment: CEO Carole Ben-Maimon, CFO Michael Celano, COO John B. Jr. Harlow, insider Gopi Shankar, and directors Frank Thomas and Joseph Truitt together purchased 52,810 shares for roughly $195,000. Director Thomas Hamilton separately bought 70,000 shares for $186,900. Insider purchase report Hamilton SEC filing
- Neutral Sentiment: The supplied coverage also notes H.C. Wainwright maintained a Buy rating; no rating change or fresh price-moving catalyst was reported. Analyst rating report
Analyst Ratings Changes
Several research firms have commented on LRMR. Wall Street Zen lowered shares of Larimar Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Wedbush reaffirmed an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Larimar Therapeutics in a research report on Thursday, October 15th. Finally, Leerink Partners started coverage on shares of Larimar Therapeutics in a research report on Monday, September 14th. They set an “outperform” rating and a $13.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $10.33.
Check Out Our Latest Stock Report on LRMR
Larimar Therapeutics Stock Performance
The company has a market cap of $313.72 million, a price-to-earnings ratio of -1.55 and a beta of 0.73. The business has a fifty day moving average price of $2.93 and a 200 day moving average price of $3.76.
Insider Activity at Larimar Therapeutics
In related news, COO John B. Jr. Harlow bought 17,800 shares of the company’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average price of $2.80 per share, with a total value of $49,840.00. Following the completion of the acquisition, the chief operating officer owned 67,800 shares of the company’s stock, valued at $189,840. The trade was a 35.60% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Celano purchased 18,460 shares of Larimar Therapeutics stock in a transaction dated Wednesday, November 11th. The stock was bought at an average price of $2.71 per share, for a total transaction of $50,026.60. Following the completion of the purchase, the chief financial officer owned 234,245 shares in the company, valued at $634,803.95. This represents a 8.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 140,810 shares of company stock worth $381,955 over the last three months. 4.00% of the stock is owned by insiders.
Institutional Trading of Larimar Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the stock. Blue Owl Capital Holdings LP grew its stake in shares of Larimar Therapeutics by 0.3% during the third quarter. Blue Owl Capital Holdings LP now owns 9,923,904 shares of the company’s stock worth $31,707,000 after buying an additional 32,147 shares during the last quarter. BlackRock Inc. bought a new position in shares of Larimar Therapeutics in the 2nd quarter valued at $17,318,000. Marshall Wace LLP lifted its stake in shares of Larimar Therapeutics by 9.1% in the 3rd quarter. Marshall Wace LLP now owns 2,195,954 shares of the company’s stock valued at $7,005,000 after acquiring an additional 183,496 shares during the last quarter. AIGH Capital Management LLC acquired a new stake in shares of Larimar Therapeutics during the 3rd quarter valued at $5,911,000. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Larimar Therapeutics by 143.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 798,462 shares of the company’s stock valued at $3,592,000 after acquiring an additional 470,968 shares in the last quarter. Institutional investors and hedge funds own 91.92% of the company’s stock.
About Larimar Therapeutics
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Bala Cynwyd, Pennsylvania, focused on developing treatments for rare diseases. Its lead drug candidate is nomlabofusp, formerly known as CTI-1601, an engineered fusion protein designed to deliver frataxin to mitochondria. Nomlabofusp is being developed to treat Friedreich’s ataxia, a rare, inherited neurodegenerative disorder associated with insufficient frataxin. Larimar’s approach uses a cell-penetrating peptide to transport frataxin into cells and mitochondria, with the goal of addressing an underlying cause of the disease rather than only treating its symptoms.
Further Reading
- Five stocks we like better than Larimar Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
